In the following video, Motley Fool health-care analyst David Williamson looks at two major pieces of news surrounding biotech company Gilead (GILD 0.58%) that show that the company has a bright future ahead. He discusses another 100% cure rate for the company in the hepatitis-C space, and a new once-daily HIV drug for the company, with a better safety profile than the competition.
This Biotech's Run Is Far From Done
By Dave Williamson – Mar 5, 2013 at 5:48PM
NASDAQ: GILD
Gilead Sciences
Market Cap
$147B
Today's Change
(-0.58%) $0.69
Current Price
$118.15
Price as of November 10, 2025 at 4:00 PM ET
Two pieces of news that show Gilead still has plenty of room to run.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid